Introduction
============

Gastric cancer (GC) is the fourth most common cancer and second leading cause of cancer-related deaths worldwide.[@b1-ott-8-2519] The mechanism of gastric carcinogenesis remains elusive. Environmental and genetic factors possibly play a role in the etiology of the disease.[@b2-ott-8-2519],[@b3-ott-8-2519] However, these risk factors cannot fully explain the development of GC, since only a minority of exposed population finally developed GC, indicating possible interplay between risk factors and personal background including genetic susceptibility.[@b4-ott-8-2519] Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes involved in physiological and pathological extracellular matrix processing, capable of degrading essentially all extracellular matrix components.[@b5-ott-8-2519],[@b6-ott-8-2519]

MMPs are divided into five structural families, including collagenases, gelatinases, stromelysins, matrilysins, and membrane-type MMPs. More evidence indicates that many MMPs are involved in tumorigenesis by modulating cell proliferation, apop-tosis, and angiogenesis.[@b7-ott-8-2519] *MMP1*, located on 11q22.3, is one member of the MMP family and degrades interstitial collagen types I, II, and III. The expression level of *MMP1* gene is at low level in normal cells under physiological conditions;[@b8-ott-8-2519],[@b9-ott-8-2519] however, *MMP1* expression is dramatically increased in many malignancies.[@b5-ott-8-2519],[@b10-ott-8-2519] It has been reported that the promoter of *MMP1* can regulate *MMP1* gene transcription, in which there is a functional single nucleotide polymorphism (SNP), *MMP1*−1607 1G\>2G (rs1799750),[@b11-ott-8-2519],[@b12-ott-8-2519] which contains a guanine insertion/deletion polymorphism at position −1607[@b13-ott-8-2519] and leads to higher expression of *MMP1*. In the current study, we performed a meta-analysis of hospital-based studies to determine the association between the *MMP1*−1607 1G\>2G polymorphism and GC risk.

Materials and methods
=====================

Study strategy
--------------

A systematic computerized search in all the electronic databases that could search for literatures, including PubMed, Chinese National Knowledge Infrastructure (CNKI), EMBASE and Elsevier Science Direct etc, was conducted to collect all case-control studies evaluating *MMP1* and GC in humans published until August 2014. The search was developed without any language restriction and searching for the following terms: (matrix metalloproteinase-1 OR *MMP1*), (polymorphism OR polymorphisms OR variant OR variants OR genotype), and (cancer OR carcinoma OR neoplasm). To expand our research, we also performed the search in the CNKI database using terms in Chinese, such as *MMP1*, gastric cancer risk OR GC risk, and polymorphism. The references for all identified publications were hand-searched for additional studies.

Statistical methods
-------------------

We used odds ratios (ORs) and 95% confidence intervals (CIs) to measure the strength of association between *MMP1*−1607 1G\>2G polymorphism and GC risk. Pooled ORs and 95% CIs were calculated for an allele mode, a dominant model (variant homozygote + heterozygote vs wild-type homozygote), and a recessive model (variant homozygote vs heterozygote + wild-type homozygote).

Then, we assessed an estimate of potential publication bias using the funnel plot, in which the standard error of log (SEL) of every study was plotted against its log (OR), and an asymmetric plot indicated a potential publication bias. We assessed funnel plot asymmetry using Egger's linear regression test, a linear regression method of evaluating funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined using the *t*-test suggested by Egger, and *P*\<0.05 was considered representative of statistically significant publication bias. All of the statistical tests were performed using STRATA version 12.0 (StrataCorp, College Station, TX, USA).

Data extraction
---------------

The following basic data were collected from the studies that met the inclusion criteria: first author's name, tumor type, year of publication, country, ethnicity of study population, number of cases and controls, and genotyping method. Two independent investigators conducted data extraction work, and they resolved discrepancies through discussion. Study qualities were judged according to the criteria modified from a previously published study[@b14-ott-8-2519] ([Table S1](#SD1-ott-8-2519){ref-type="supplementary-material"}).

Results
=======

Eligible study characteristics
------------------------------

A total of 649 publications, all written in English or Chinese and all extracted from the PubMed, MEDILINE, EMBASE, and CNKI databases, were reviewed. Finally, six articles[@b15-ott-8-2519]--[@b20-ott-8-2519] containing six studies, including 1,377 GC cases and 1,543 non-cancer controls were included in the current meta-analysis. A flowchart shows the study selection procedure ([Figure 1](#f1-ott-8-2519){ref-type="fig"}). The main characteristics of the studies are listed in [Table 1](#t1-ott-8-2519){ref-type="table"}. Sample sizes and *MMP1*−1607 1G\>2G allele and genotype distributions in the studies considered in the present meta-analysis are shown in [Table 2](#t2-ott-8-2519){ref-type="table"}.

Quantitative synthesis
----------------------

The fixed-effects model is used in the current meta-analysis. The association between the *MMP1*−1607 1G\>2G polymorphism and cancer risk was estimated with the following models: an allele model (2G vs 1G), a dominant model (2G/2G + 1G/2G vs 1G/1G), and a recessive model (2G/2G vs 2G/1G + 1G/1G). The evaluations of the association of *MMP1*−1607 1G\>2G with cancer risk are shown in [Table 3](#t3-ott-8-2519){ref-type="table"}. In the allele model (2G vs 1G), the overall pooled effect showed that the 2G allele was associated with an increased overall cancer risk, compared with the 1G allele (OR =1.05; 95% CI, 1.01--1.08) ([Figure 2A](#f2-ott-8-2519){ref-type="fig"}). In the recessive model (2G/2G vs 2G/1G + 1G/1G), the overall pooled effect showed that the 2G/2G homozygote was not associated with an overall cancer risk, compared with the 2G/2G + 1G/1G homozygote (OR =1.06; 95% CI, 0.98--1.14) ([Figure 2B](#f2-ott-8-2519){ref-type="fig"}). In the dominant model (2G/2G + 1G/2G vs 1G/1G), the overall pooled effect demonstrated that the 2G/2G + 1G/2G genotypes were associated with a significantly increased overall cancer risk, compared with the 1G/1G homozygote (OR =1.11; 95% CI, 1.08--1.15) ([Figure 2C](#f2-ott-8-2519){ref-type="fig"}).

Heterogeneity analysis
----------------------

Heterogeneity was assessed using the *χ*^2^-based *Q*-test among studies in the overall comparisons analysis. Heterogeneity was found in the pooling models (*P*\<0.1 in all models); thus, the fixed-effects model was used to produce an extended pool of studies with 95% CIs. No significant heterogeneity can be seen among the six comparisons using the dominant model, recessive model, or allelic contrast.

Publication bias
----------------

For *MMP1*−1607 1G\>2G, Begg's funnel plot and Egger's test provided no evidence of publication bias in an allele model (2G vs 1G, Egger's test: 95% CI, −4.65 to −4.81, *P*=0.964; Begg's test: *P*=0.851). Similarly, there was no evidence of publication bias for *MMP1*−1607 1G\>2G in a dominant model (2G/2G + 1G/2G vs Egger's test: 95% CI, −6.78 to −3.50, *P*=0.425; Begg's test: *P*=0.75), and in a recessive model (2G/2G vs 1G/2G + 1G/1G, Egger's test: 95% CI, −7.48 to −6.22, *P*=0.81; Begg's test: *P*=0.851) ([Figure 3](#f3-ott-8-2519){ref-type="fig"}). These findings demonstrated that publication bias, if any, did not significantly affect the results of our current meta-analysis for the association between *MMP1*−1607 and GC risk.

Discussion
==========

MMPs can degrade the extracellular matrix and basement membrane, which is an important event in many physiological and pathological processes, including tumor invasion and metastasis. MMP expression has been found in a variety of human tumors and is significantly correlated with tumor invasion, metastasis, and therapeutic response.[@b21-ott-8-2519] However, certain members of the MMP family exert contradicting roles at different stages during cancer progression, depending upon other factors and upon the tumor stage, tumor site, enzyme localization, and substrate profile.[@b22-ott-8-2519]

The expression level of the *MMP1* gene was found to be increased in various tumors and was related to a poor prognosis in several types of cancers. *MMP1* expression can be regulated by the *MMP1* promoter. The polymorphism at position −1607 among the *MMP1* promoters determined the increased *MMP1* transcriptional level, which is attributed to its 2G allele generating a core-binding site for the E26 transformation-specific (ETS) transcription factor family, leading to the increased *MMP1* expression.[@b23-ott-8-2519]

There were six articles[@b15-ott-8-2519]--[@b20-ott-8-2519] containing six studies, including 1,377 GC cases and 1,543 non-cancer controls used in the present meta-analysis. The procedure of meta-analysis was performed by using STRATA version 12.0 software. We found that individuals with the 2G allele and 1G/2G + 2G/2G genotypes had a higher risk of GC for all models, including allele and dominant models. Interestingly, in a recessive model, there was no significant difference between 2G/2G genotype and 1G/2G + 1G/1G genotypes. These results indicated that 2G allele and heterozygote 2G might affect the individual's phenotype more than other genotypes; the 2G allele or 1G/2G genotype carriers therefore seemed more susceptible to cancer development than 1G allele genotype carriers, or 1G/1G genotype carriers.

In the past several years, other studies have also found that the 2G allele is associated with an increased risk of other cancers. Zhang et al[@b12-ott-8-2519] have reported that the *MMP1*−1607 1G\>2G polymorphism is associated with an increased risk of head and neck cancer. Hu et al's results showed that the *MMP1* rs1799750 polymorphism is associated with a decreased risk of lung cancer in Asian, but not in Caucasian subjects.[@b24-ott-8-2519] Taken together, the relationship between *MMP1* rs1799750 polymorphism and cancer risk may be disease-specific and may depend on other factors, such as race, age, habits, etc. There are another two studies that relate to GC and *MMP1*, included in Li et al (2013)[@b25-ott-8-2519] and Yang et al (2014).[@b26-ott-8-2519] Meanwhile, Li's study[@b14-ott-8-2519],[@b25-ott-8-2519] gathered data before August 2011, and Yang's before June 2013. In our results, there are four more studies involved, indicating the advantages of our study compared to previously published similar studies.

Recently, multiple therapeutic agents named matrix metalloproteinase inhibitors (MMPIs) have been developed to target MMPs and to control their enzymatic activity.[@b22-ott-8-2519] *MMP1*−1607 1G\>2G polymorphism may be regarded as a target of MMPIs in treatment of GC in the future.

Study limitations
-----------------

There are some limitations to the current study. First, we have collected all eligible studies, but the study number was not large and the numbers of patients examined were small. Second, we did not assess the potential effects of other factors such as differences in race. Third, only one SNP in *MMP1* was included in this study. Some other SNPs in *MMP1* also could contribute to susceptibility to GC. The effects of these SNPs and the interaction or network among these related genes should also be studied in the future.

Conclusion
==========

In conclusion, our present meta-analysis indicates that *MMP1*−1607 1G\>2G polymorphism is associated with GC risk. However, our results should be further validated with larger samples and in different ethnic populations, due to the limited study numbers and relatively small sample sizes.

Supplementary material
======================

###### 

Scale for methodological quality assessment

  Criteria                                                              Score
  --------------------------------------------------------------------- -------
  1\. Representativeness of cases                                       
   Gastric cancer diagnosed according to acknowledged criteria          2
   Mentioned the diagnosed criteria but not specifically described      1
   Not mentioned                                                        0
  2\. Source of controls                                                
   Population or community-based                                        3
   Hospital-based GC-free controls                                      2
   Healthy volunteers without total description                         1
   GC-free controls with related diseases                               0.5
   Not described                                                        0
  3\. Sample size                                                       
   \>300                                                                2
   200--300                                                             1
   \>200                                                                0
  4\. Quality control of genotyping methods                             
   Repetition of partial/total tested samples with a different method   2
   Repetition of partial/total tested samples with the same method      1
   Not described                                                        0
  5\. Hardy--Weinberg equilibrium (HWE)                                 
   Hardy--Weinberg equilibrium in control subjects                      1
   Hardy--Weinberg disequilibrium in control subjects                   0

**Abbreviation:** GC, gastric cancer.
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![Flowchart of study selection procedure of this meta-analysis.\
**Abbreviations:** EMBASE, Excerpta Medica Database; CNKI, Chinese National Knowledge Infrastructure; *MMP1*, matrix metalloproteinase-1.](ott-8-2519Fig1){#f1-ott-8-2519}

###### 

Meta-analysis of the association between GC and the *MMP1*--1607 1G\>2G polymorphisms.

**Notes:** (**A**) *MMP1*--1607 1G\>2G allele model (2G vs 1G), among all populations in the fixed-effects model. (**B**) *MMP1*--1607 1G\>2G recessive model (2G/2G vs 1G/2G + 1G/1G), among all populations in the fixed-effects model. (**C**) *MMP1*--1607 1G\>2G dominant model (2G/2G + 1G/2G vs 1G/1G), among all populations in the fixed-effects model.

**Abbreviations:** OR, odds ratio; CI, confidence interval; *MMP1*, matrix metalloproteinase-1; GC, gastric cancer; vs, versus.
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![Begg's funnel plot for publication bias test. Each point represents a separate study for the indicated association. Log (OR) is the natural logarithm of OR. Horizontal line is the effect size.\
**Notes:** (**A**) *MMP1*--1607 1G\>2G, 2G vs 1G; (**B**) *MMP1*--1607 1G\>2G, 2G/2G vs 1G/2G + 1G/1G; (**C**) *MMP1*--1607 1G\>G, 2G/2G + 1G/2G vs 1G/1G.\
**Abbreviations:** SE, standard error; OR, odds ratio; *MMP1*, matrix metalloproteinase-1; vs, versus.](ott-8-2519Fig3){#f3-ott-8-2519}

###### 

Characteristics of individual studies included in the current meta-analysis

  First author's name (year)   Country                      Genotype method   Selection/characteristics of cases                                                                                                                                                         Selection/characteristics of controls                                             Ref
  ---------------------------- ---------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------- -------------------
  Matsumura et al (2004)       Japan                        PCR-RFLP          215 gastric cancer patients, 153 males and 62 females (median age 67.7±11.4 years), including 122 patients with an intestinal type of gastric cancer and 93 patients with a diffuse type   166 healthy control subjects, 95 males and 71 females                             [@b20-ott-8-2519]
  Jin et al (2005)             People's Republic of China   PCR               183 patients with gastric cardiac adenocarcinoma, 134 males and 49 females, average age 55.0±10.5 years                                                                                    350 healthy individuals, 229 males and 121 females, average age 51.7±10.7 years   [@b19-ott-8-2519]
  Fang et al (2013)            People's Republic of China   PCR-RFLP          246 gastric cancer patients, 163 males and 83 females, average age 57.9±11.8 years                                                                                                         252 normal controls, 167 males and 85 females, average age 58.8±11.2 years        [@b18-ott-8-2519]
  Devulapalli et al (2014)     India                        PCR-RFLP          166 gastric cancer patients, 118 males and 48 females, 82.53% ≥50 years                                                                                                                    202 normal controls, 132 males and 70 females, 62.37% ≥50 years                   [@b16-ott-8-2519]
  Dey et al (2014)             India                        PCR               145 gastric cancer patients, 112 males and 33 females, range 42.6--65.8 years                                                                                                              145 normal controls, 81 males and 64 females, range 34.5--62.5 years              [@b17-ott-8-2519]
  Hua et al (2014)             People's Republic of China   PCR               422 gastric cancer patients, 237 males and 185 females, range 42.2±5.6 years                                                                                                               428 gastric cancer patients, range 43.3±4.6 years                                 [@b15-ott-8-2519]

**Note:** Equations show data are presented as mean ± standard deviation.

**Abbreviations:** PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.

###### 

Sample sizes and *MMP1*--1607 1G\>2G allele and genotype distributions in the studies considered in the present meta-analysis

  Gene           First author's name (year)                  Cases   Controls   HWE of control (*P*-value)   Frequency of 1G allele in controls   Quality[\*](#tfn3-ott-8-2519){ref-type="table-fn"}                                                                    
  -------------- ------------------------------------------- ------- ---------- ---------------------------- ------------------------------------ ---------------------------------------------------- ----- ----- ----- ----- ---- ----- ----- ------------ ---------- ---
  *MMP1*--1607   Matsumura et al[@b20-ott-8-2519] (2004)     215     101        88                           26                                   290                                                  140   166   88    61    17   237   95    Y (0.1953)   0.713855   7
  1G/2G          Jin et al[@b19-ott-8-2519] (2005)           183     112        51                           20                                   275                                                  91    350   194   105   51   493   207   N (0.0000)   0.704286   7
                 Fang et al[@b18-ott-8-2519] (2010)          246     155        85                           6                                    395                                                  97    252   161   78    13   400   104   Y (0.3826)   0.793651   7
                 Devulapalli et al[@b16-ott-8-2519] (2014)   166     46         114                          6                                    206                                                  126   202   50    130   22   230   174   N (0.0000)   0.569307   7
                 Dey et al[@b17-ott-8-2519] (2014)           145     56         66                           23                                   178                                                  112   145   53    72    20   178   112   Y (0.2713)   0.613793   6
                 Hua et al[@b4-ott-8-2519] (2014)            422     186        187                          49                                   559                                                  285   428   158   195   75   511   345   Y (0.5686)   0.596963   7

**Note:**

Represents the confidence of the study.

**Abbreviations:** *MMP1*, matrix metalloproteinase-1; HWE, Hardy--Weinberg equilibrium; N, number of subjects.

###### 

Meta-analysis of the association between the studied *MMP1* alleles and GC in different populations

  Gene           Genotypes                Group   Fixed-effects model   Heterogeneity                         
  -------------- ------------------------ ------- --------------------- --------------- ------- ------ ------ -------
  *MMP1*--1607   2G vs 1G                 Total   1.05 (1.01--1.06)     2.49            0.013   9.21   45.7   0.101
  1G/2G          2G/2G vs 2G/1G + 1G/1G   Total   1.06 (0.989--1.14)    1.52            0.129   6.57   23.9   0.254
                 2G/2G + 2G/1G vs 1G/1G   Total   1.11 (1.08--1.15)     6.14            0.000   4.51   0      0.478

**Abbreviations:** GC, gastric cancer; *MMP1*, matrix metalloproteinase-1; OR, odds ratio; CI, confidence interval; vs, versus.
